Pharmaceutical Industry News Archive
Get news by email or subscribe to our news feeds.
News Archive for March 2011
March 1, 2011
- Elan Drug Firm to Pay $203 Million in Penalties
- Daiichi Sankyo to Buy Plexxikon for $805 Million
- Daiichi Sankyo to Acquire Plexxikon
- MediGene Completes the Transfer of Eligard Rights for EU Countries to Astellas
- Genzyme Completes Sale of Pharmaceuticals Business to International Chemical Investors Group
- US Supreme Court Denies Certiorari and Thereby Leaves in Place Second Circuit Ruling That Novartis Pharmaceuticals Corporation Must Pay its Sales Representatives Overtime Compensation
- Perrigo Announces Arrival of the FDA for Reinspection Related to the Allegan Facility Warning Letter
- K-V Pharmaceutical Company Announces $200 Million Private Debt Offering
March 2, 2011
- FDA Drug Safety Communication: Safety Review Update of Abacavir and Possible Increased Risk of Heart Attack
- Elan Pharmaceuticals Pleads Guilty, Sentenced for Off-Label Marketing of Zonegran
- FDA MedWatch - Abacavir - Ongoing Safety Review: Possible Increased Risk of Heart Attack
- Galapagos delivers candidate drug in GSK alliance, receives ?6.7 million
- GTx and Ipsen Terminate Their Toremifene Collaboration
- California Supreme Court Reinstates Baycol Class Action Appeal
- European Commission Continues to Support Avastin in Combination With Paclitaxel As An Effective Treatment Option for Women With Metastatic Breast Cancer
- FDA Prompts Removal of Unapproved Drugs From Market
March 3, 2011
- FDA Drug Safety Communication: Low Magnesium Levels Can be Associated with Long-term Use of Proton Pump Inhibitor Drugs (PPIs)
- Forest Pharmaceuticals Sentenced to Pay $164 Million for Criminal Violations
- Renovo Group Plc Announces Major Restructuring & Conference Call
- Lycera Announces Research Collaboration with Merck to Discover, Develop and Commercialize Drugs for Autoimmune Diseases
- Targacept Announces Termination of Strategic Alliance Agreement with GlaxoSmithKline
- Intermune Gets European Approval for Lung Drug
- Sanofi Plans Autonomy for Part of Genzyme Business
- Public statement on Thelin: Withdrawal of the marketing authorisation in the European Union
- AstraZeneca Joins Sanofi-Aventis to Develop New TB Treatment
March 4, 2011
- U.S. FDA Removes Warning about Potential Liver Injury from Boxed Warning of Prescribing Information for Gilead's Letairis
- Lannett Comments on News Article
- Lawsuit Blames Hair Loss Drug for Sexual Dysfunction And Mental Problems
- FDA: Risk of oral birth defects in children born to mothers taking topiramate
- Intra-Cellular Therapies and Takeda Enter into Worldwide Collaboration to Develop and Commercialize Compounds for Schizophrenia
- Human Brain Cells Grown In Lab May Help Fight Alzheimer's
- NICE consults on a new drug to treat diabetic macular oedema
March 7, 2011
- FDA Drug Safety Communication: Liver Injury Warning to be Removed from Letairis (ambrisentan) Tablets
- Japan Drops Two Vaccines After Four Deaths
- Sanofi-Aventis Prolongs Offer For Genzyme Until 1 April
- Drugmakers Wait For FDA to Rule
- AstraZeneca and Galderma Enter into R&D Collaboration to Develop New Treatments for Dermatological Diseases
- Amgen Completes Acquisition of BioVex
- Glaxo on Target With New Women Directors
- How Are Physicians Responding to the FDA's Bad Ad Program?
- AstraZeneca to Discontinue Production of Pulmicort PMDI, Other Respiratory Medicines Not Affected
- FDA Approves Revised Alphanate Labeling to Include Reduced Infectivity of an Experimental Model Agent for vCJD
- Cephalon Names J. Kevin Buchi as New CEO: PharmaLive Special Reports
March 8, 2011
- Amicus Therapeutics Announces FDA Agreement to Commence Phase 2 Study of AT2220 Co-administered with Enzyme Replacement Therapy for Pompe Disease
- Merz Pharmaceuticals Introduces Comprehensive Programs to Provide Patients With Financial Assistance for Xeomin (incobotulinumtoxinA)
- Hospira Board Names F. Michael Ball New CEO; Christopher B. Begley to Assume Executive Chairman Role
- Eisai Realigns Its U.S. Operations
- Hospira Names Ball New CEO
- Genzyme's Chief to Get $160 Million From Sale
- Allergan Board of Directors Announces Departure of President F. Michael Ball; Chairman of the Board and Chief Executive Officer David E.I. Pyott Resumes Role as President
- Vanda Sleep Disorder Drug Getting EU Incentives
March 9, 2011
- FDA Drug Safety Communication: Serious Health Problems Seen in Premature Babies Given Kaletra (lopinavir/ritonavir) Oral Solution
- J&J Secures 98.89% of Crucell Shares
- Quintiles to Borrow Billions, Plays Coy
- FDA MedWatch - Kaletra (lopinavir/ritonavir): Label Change - Serious Health Problems in Premature Babies
- Lilly CEO Calls for Biopharmaceutical Industry Changes and Policies That Encourage Medical Innovation
- Senate Passes Bill to Overhaul Patent System, Speed Up Patent Approvals
March 10, 2011
- Medical Experts Say First New Lupus Drug Since 1950s Could Spur More Research on Disease
- Lilly Announces New Vice President of Oncology Research
- ARYx Therapeutics Informed of Additional Delay by FDA and Begins Wind-Down of Operations
- Tranzyme Moves Closer to IPO
- Massachussetts: Hedge Fund Chief Profited From Inside Information
- Former KV Chief to Appear on Criminal Charge
- Johnson & Johnson Say Risks of the Drug Risperdal Were Disclosed
- Japan Says Pfizer, Sanofi Vaccines Did Not Cause Pediatric Deaths
March 11, 2011
- AstraZeneca Will Pay $2.4 Million
- Patients File Suit Against Drug Manufacturer
- Former CEO of KV Pharmaceutical Pleads Guilty to Misbranding Drugs and Agrees to Pay U.S. $1.9 Million in Fines and Forfeiture
- Expert Analysis of Over 300,000 Marketed OTC Products: PharmaLive Special Report
- Valeant Pharmaceuticals Completes Acquisition of PharmaSwiss S.A.
- Lilly Is Confident of Amyvid FDA Approval, Lechleiter Says
- Voluntary Recall of Hemophilus Influenza Type B Conjugate Vaccine ?Acthib?
- Dendreon Expands Launch of Provenge
- Gilead Recommends Rejection of Mini-Tender Offer By TRC Capital Corporation
March 13, 2011
March 14, 2011
- Bayer Adds 75 Jobs in PA
- Court Rules Against Cephalon
- Glaxo's Open Office Plans Make 'Mine' A Thing of the Past
- Teva Workers in Japan Slept in Factory After Quake
- FDA's Fast-Track Approval of Makena Could Backfire on KV
- Walgreen Accused of Selling Medical Information
- Court Rules on First Set of Patents in Fentora Litigation
- Topotarget Announces Updates on Belinostat in Two Clinical Trials - NSCLC and Ovarian Cancer
- GAO: Prescription Drugs: Trends in Usual and Customary Prices for Commonly Used Drugs
March 15, 2011
- Analyst Sees Impax Potential
- Japanese Biotechs Weigh Quake, Tsunami Damages
- Top Executives at Targacept Get Big Raises
- Merck Scouts for Marketing, Licensing Pacts With Indian Firms
- Laboratory for Malignancy Control Research
- Incyte Cancer Drug Meets Goal in Europe Study
March 16, 2011
- Heart Rhythm Drug Multaq May Cause Liver Injury in Some Patients: Health Canada
- Pfizer May be Turning its Attention to New Drugs
- R&D Investment by U.S. Biopharmaceutical Companies Reached Record Levels in 2010
- OSI, Genentech, Pfizer and Teva Reach Settlement Agreement in Tarceva Patent Case
- MorphoSys AG (DE) - MorphoSys Signs Manufacturing Agreement with Boehringer Ingelheim
- Research Unit Going to China, Pfizer says Company Plans Gradual Move of Antibacterials Operations to Shanghai
- FDA, EMA Announce Pilot for Parallel Assessment of Quality by Design Applications
March 17, 2011
- Amylin, Takeda Stop Mid-stage Study of Combination Treatment for Obesity
- Astellas Exercises Option to Purchase Maxygen's Interest in Perseid
- St. Louis Drug Maker Exhausting Stores of Anti-Radiation Medicine
- J&J CEO's Pay Fell 9 Per Cent Last Year Amid Medicine Recalls and Declining Sales
- Mooresville Firm Sends Pills to Quake Zone
- Depomed Regains Rights to Gralise From Abbott Labs
- Human Genome Sciences Inks Cancer Drug Deal
- Kantar Media Reports U.S. Advertising Expenditures Increased 6.5 Percent in 2010
- Amylin and Takeda Voluntarily Suspend Clinical Activities in Obesity Trial
- Genfit Signs A New Research Contract on Metabolic Disorders With Sanofi-Aventis
- Human Genome Sciences and FivePrime Therapeutics Announce Development and Commercialization Agreement for Novel Anti-Cancer Drug
- Dainippon Sumitomo Pharma: Impact of the Tohoku Earthquake
- One Lot of Vaccine Against Japanese Encephalitis Is Subject of Recall
- New Drug Combo for Hepatitis C Shows Promise
March 18, 2011
- Mylan Pharmaceuticals Recalls Two Drugs Due to Label Mixup, Could Pose Risk
- Sen. Brown Leads Effort to Demand Federal Investigation Into Price Gouging of Pre-Term Labor Drug for Expectant Mothers
- Sage Bionetworks Announces Cancer Partnership with AstraZeneca
- Medicare Won't Set New Rules on Anemia Drugs
- Novartis Jobs Cut
- Lilly Warns Against Use of Alcohol Prep Pads By Triad Group Included in Forteo Starter Kits
March 21, 2011
- Cell Therapeutics Initiates Pixantrone PIX-R Pivotal Trial for Treatment of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Genentech Announces Positive Pivotal Phase II Results for Hedgehog Pathway Inhibitor in Advanced Basal Cell Carcinoma
- Glaxo Boss Attacks Firms That Quit UK to Avoid Tax
- Morgan Stanley Reports Mylan Seeking FDA Approval of Generic Lipitor in June 2011 for Watson Pharmaceuticals
- Ciaran Bellwoar Joins Siren Interactive; Announcing New Philadelphia Office
- Chewable Viagra Soon Available in Mexico
- After Cuts, Inspire to Pay Bonuses
- Medco Paid Millions to Calpers Bribery Suspect
- Calif. Says Bristol-Myers Paid Off Doctors
- FDA Sends Letter to Taro Over Ovide Promotion
- FDA Sends Letter to AMAG Pharmaceuticals Over Feraheme
- Insurance Commissioner Dave Jones Intervenes in Lawsuit Against Pharmaceutical Giant Bristol Myers-Squibb Alleging Illegal Kickbacks Provided to Doctors to Increase Sales of Its Drugs
- Curis, Genentech Announce Cancer Drug Study Result
- Branded Pharmaceutical Websites Continue to Be Most Impactful in Driving Conversions Among Prospects and Patients
- Cephalon Announces Definitive Agreement to Acquire Gemin X
March 22, 2011
- New Analysis Illustrates the Hidden Burden of Atrial Fibrillation on Healthcare Spending and Resources in Each State
- Launch of Reminyl for the treatment of Japanese patients with Alzheimer-type dementia
- Labopharm Announces Workforce Reduction and Appointment of New Cfo
- Seattle Genetics Announces Antibody-Drug Conjugate Collaboration with Abbott
- EMDT, MD+DI, and Qmed Announce Virtual Event Dedicated to Developments in Materials for Medical Applications
March 23, 2011
- Pozen Announces Licensing Deal with Cilag GmbH, A Division of Johnson & Johnson, for MT 400, Migraine Treatment
- Patent System Reforms Could Squeeze Out Start-Ups
- Former Pfizer CEO Kindler Saw 2010 Compensation Swell 60 Per Cent Partly Due to Severance
- Pozen Inks Deal With J&J Company for Migraine Drug
March 24, 2011
- Sanofi-aventis Enters Into Research Collaboration With Columbia University to Develop New Diabetes Treatments
- House Bill Would Shield Drug Makers
- GSK Scraps Plans To Market Prostate-Cancer Drug
- Generic Drug Info On Website
- Portola Pharmaceuticals to Regain Global Rights for Investigational Medicine Betrixaban from Merck
- The Procter & Gamble Company and Teva Pharmaceutical Industries Form Consumer Health Care Partnership
- AltheRx Completes Acquisition of First Product Solabegron from GlaxoSmithKline
- Proton Pump Inhibitors (PPI): Class Labeling Change
- Landmark Ruling Comes into Effect: Treatment Now Available for People in England and Wales With Mild Alzheimer's At Time of Diagnosis
- NeuroSearch Provides An Update on the Development Plan for Huntexil in the Treatment of Huntington's Disease Following the End of Phase II Meeting With the FDA
- Portola Regains Product Rights From Merck
- Neurosearch to Need More Money for Extra Trials With Huntexil
- HCPC Expands Annual Event to Drive Pharma Collaboration
March 25, 2011
- Med Ad News Magazine Announces Nominees for the 22nd Annual Manny Awards as well as Advertising Person of the Year
- Pfizer Past CEO Steere, a Key Company Builder Retires From Its Board
- Chinese Drug Maker Aids Local Biotech Firm
- PPD Names 3 Candidates for Board of Directors
- Watson Confirms District Court Ruling in Generic Fentora Patent Suit
- Penn Researchers Uncover Novel Immune Therapy for Pancreatic Cancer
- Takeda Plans to Expand the Sales Force and to Enhance the business infrastructure in China
March 28, 2011
- Senator Calls for Probe Into Makena's Cost Hike
- UK and US Governments Reach Agreement Over AstraZeneca Tax Matters
- AstraZeneca to Pay $1 Billion+ to Resolve U.S. Tax Dispute
- Skin Cancer Drug From Bristol Myers Is First Approved By US Regulators In 13 Years
- Quintiles Reaches New Milestone in Social Health
- Watson Pharma Sued Over Planned Generic Oxycontin
- Greenstone Announces Voluntary Nationwide Recall of Citalopram and Finasteride Due to Possible Mislabeling
- Not-For-Profit Proposal Would Save 25 Jobs Affected By Layoffs At Pfizer
- APP Pharmaceuticals Issues a Nationwide Voluntary Recall of Irinotecan Hydrochloride Injection
- Drug Shortages Cost U.S. Care Providers at Least $200 Million Annually, Pose Patient Safety Risks, Research Suggests
- FDA MedWatch - Irinotecan Hydrochloride Injection: Recall - Fungal Microbial Contaminant
- Drug Shortages Alarm, Perplex Medical Staff
- Greenstone Voluntary Recalls Citalopram And Finasteride Nationwide Due to Possible Mislabelling
- BioPharm Asia in Negotiations to Acquire Hubei Holley Zhengyuan Pharmaceutical Company Limited
- Ecron Acunova Strengthens Clinical Research Presence in Nordic Countries by Acquiring Majority Stake in aCROnordic
March 29, 2011
- AARP: Drug Prices Up Before Patent Expires
- Cephalon To Make Takeover Bid for Chemgenex
- GSK Raises Bar for Green Initiatives and Charity
- More Drug Firms Settle
- Cephalon to Launch $231 Million Takeover Bid for Australian ChemGenex
- Institut Pasteur Shanghai Announces the Creation of its Global Biotech Accelerator Advance BioChina
- Conflicts of Interest Are Prevalent Among Writers, Reviewers of Cardiovascular Clinical Practice Guidelines
- A New Pharmaceutical Candidate Enters Lundbeck's Development Pipeline
- Access Hollywood to Interview Actor Eric Roberts About Genmed Endorsement
- AARP Report Finds Spikes in Drug Prices as Patents Expire
- Pharmathene Reports Wider 2010 Loss
- Biosimilar Market Will Reach $3.7 Billion in 2015
- Important Drug Information Notice Regarding Sodium Thiosulfate Injection, USP, 10% (100mg/mL), 10mL Single Dose Vials and 25% (250mg/mL), 50mL Single Dose Vials
- Sanofi-aventis Announces Registration Statement for CVR Related to Genzyme Acquisition Declared Effective
- Cephalon Launches Recommended Takeover Bid For Australian Biopharmaceutical Company, Chemgenex Pharmaceuticals Limited
March 30, 2011
- Valeant Pharma Makes Hostile US$ 5.7 Billion Bid for U.S.-based Cephalon
- Dainippon Sumitomo Pharma and Intercept Pharmaceuticals Announce Agreement to Develop and Commercialize Obeticholic Acid (INT-747) for Chronic Liver Disease
- Amgen Cancer Drug Fails In Late-Stage Study
- Lawyers Say Former Merck Plant Leaked Toxic Chemical For Years
- Takeda and DSP Sign Development, Manufacturing and Commercialization Agreement for a Cephem Antibiotic Ceftaroline in Japan
- DSP and Takeda Sign Development and Commercialization Agreement for an Atypical Antipsychotic Agent Lurasidone in Europe
- Eisai and Minophagen Pharmaceutical Conclude Japan License Agreement for Cutaneous T-Cell Lymphoma Treatment Bexarotene
- Myrexis Reorganizes to Align Resources With Current Pipeline
- Swedish Orphan Biovitrum AB (publ) (SE) -Decision on Cost Savings to Create Profitable Growth
- CDC and ADPH Investigate Outbreak at Alabama Hospitals; Products Recalled
- Generex Unveils Strategic Development Plan
March 31, 2011
- AstraZeneca to Recruit 100 Empoyees in Swedish R&D Push
- Hepatitis C Drug Treatments Tested in Detroit Could Cure Disease
- KV Prenatal Drug Loses Exclusivity
- Attorney General Conway Announces $10 Million Settlement with Pharmaceutical Manufacturers
- US Court Seems Split in Generic Drug Case
- Biogen Idec and Knopp Biosciences Announce Enrollment of the First Patient in a Global Phase III Study of Dexpramipexole for ALS
- Dendreon Statement on CMS Proposed Decision Memo for Provenge
- Lilly's Connecting Hearts Abroad Program Sends Employees on Global Service Assignments
- GSK Publishes Payments for Research, Consulting and Advising by U.S. Healthcare Professionals
- Generic Drug Labels At Core Of Wrenching Case
- Supremes Seems Split In Generic Drug Case
- FDA Statement on Makena
- New Research Shows MDs Prefer a Mix of Digital, Face-to-Face Marketing
- Pfizer Posts Details Of Interactions With U.S. Health Care Professionals And Researchers In 2010
- Watson Announces Approval of Nulecit, the First Generic Alternative to Ferrlecit for the Treatment of Iron Deficiency Anemia
